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Clinical StudyMolecular Characterization of
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pus, superior temporal gyrus, and thalamus, appear to
be disturbed in this disorder (Harrison, 1999; McCarley
et al., 1999). In particular, a convergence of observations
from clinical, neuroimaging, and postmortem studies
have implicated the dorsal prefrontal cortex (PFC) as a
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major locus of dysfunction in schizophrenia (Weinberger‡PittArray
et al., 1986; Selemon et al., 1995; Andreasen et al., 1997;University of Pittsburgh School of Medicine
Bertolino et al., 2000). Abnormal PFC function probablyPittsburgh, Pennsylvania 15261
contributes to many of the cognitive disturbances in
schizophrenia and appears to be related to altered syn-
aptic structure and/or function in this cortical region.
For example, in subjects with schizophrenia, reductionsSummary
in gray matter volume in the dorsal PFC have been ob-
served in neuroimaging studies (Goldstein et al., 1999;Microarray expression profiling of prefrontal cortex
Sanfilipo et al., 2000), and these volumetric changesfrom matched pairs of schizophrenic and control sub-
are associated with an increase in cell packing densityjects and hierarchical data analysis revealed that tran-
(Selemon et al., 1995, 1998; Lewis and Lieberman, 2000)scripts encoding proteins involved in the regulation
but no change in total neuron number in the PFC (Pak-of presynaptic function (PSYN) were decreased in all
kenberg, 1993). Although the size of some PFC neuronalsubjects with schizophrenia. Genes of the PSYN group
populations appears to be reduced in schizophreniashowed a different combination of decreased expres-
(Rajkowska et al., 1998; Pierri et al., 1999), these findingssion across subjects. Over 250 other gene groups did
are also likely to reflect a decrease in the number ofnot show altered expression. Selected PSYN microar-
axon terminals and in the distal dendrites and dendriticray observations were verified by in situ hybridization.
spines that represent their principal synaptic targetsTwo of the most consistently changed transcripts in
(Selemon and Goldman-Rakic, 1999). Consistent withthe PSYN functional gene group, N-ethylmaleimide
this interpretation, both the levels of synaptophysin, asensitive factor and synapsin II, were decreased in ten
presynaptic terminal protein (Karson et al., 1996; Per-of ten and nine of ten subjects with schizophrenia,
rone-Bizzozero et al., 1996; Glantz and Lewis, 1997),respectively. The combined data suggest that subjects
and the density of dendritic spines (Garey et al., 1998;with schizophrenia share a common abnormality in
Glantz et al., 2000) are decreased in the PFC of subjectspresynaptic function. We set forth a predictive, testa-
with schizophrenia. Interestingly, the typical age of on-ble model.
set of schizophrenia coincides with the termination of
the adolescence-related reduction in the densities ofIntroduction
synapses and dendritic spines in the primate PFC (Hut-
tenlocher, 1979; Bourgeois et al., 1994; Anderson et al.,Schizophrenia is a complex and devastating brain disor-
1995).der that affects 1% of the population and ranks as one
Changes in gene expression also have been observedof the most costly disorders to afflict humans (Carpenter
in the PFC of subjects with schizophrenia. In particular,and Buchanan, 1994; Hyman, 2000b). This disorder typi-
alterations in gene products related to neurotransmis-cally has its clinical onset in late adolescence or early
sion (Akbarian et al., 1995a, 1996; Meador-Woodruff et
adulthood, presenting as a constellation of both positive
al., 1997; Volk et al., 2000) or second messenger systems
(delusions, hallucinations, and thought disorganization)
(Dean et al., 1997; Shimon et al., 1998; Hudson et al.,
and negative (impaired motivation and decreased emo- 1999) have been observed. However, each of these stud-
tional expression) symptoms (Lewis, 2000). Alterations ies have focused on only one or a few gene products at
in cognitive processes, such as attention and working a time, without the ability to investigate the simultaneous
memory, however, may be present prior to the onset expression of large numbers of genes. Consequently,
of the clinical syndrome and appear to represent core complex gene expression patterns in the PFC of sub-
features of the illness. In addition, many individuals with jects with schizophrenia are currently unknown.
schizophrenia experience difficulties with depression Microarray technology provides an opportunity for ap-
and substance abuse, factors that contribute to the plication of gene expression analysis to complex clinical
10%–15% lifetime incidence of suicide in this disorder. diseases (Eisen et al., 1998; Brown and Botstein, 1999;
The etiology of schizophrenia remains elusive but ap- Duggan et al., 1999; Alizadeh et al., 2000), and these
pears to be multifaceted, with genetic, nutritional, envi- approaches have been successful in addressing funda-
ronmental, and developmental factors all implicated mental biological questions in human cancer (Alizadeh
(Weinberger, 1995; Andreasen, 1996; Hyman, 2000a; et al., 2000). However, due to the inherent complexity
Pulver, 2000; Tsuang, 2000). In terms of pathophysiol- of nervous tissue and the need to utilize postmortem
ogy, a number of brain regions, including the hippocam- material, few microarray studies of the human central
nervous system have been conducted (Whitney et al.,
1999). Furthermore, in contrast to cancer, where many§ To whom correspondence should be addressed (e-mail: karoly1@
pitt.edu). biological measures of the disease reveal differences of
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several orders of magnitude, alterations in brain struc- The changes in schizophrenic subjects were assessed
by gene expression profiling for 250 gene groups relatedture or chemistry in schizophrenia appear to be much
more moderate, often not exceeding a 2-fold change to metabolic pathways, enzymes, functional pathways,
or brain-specific functions. More than 98% of the gene(Collinge and Curtis, 1991; Akbarian et al., 1995a, 1996;
Woo et al., 1998; Glantz and Lewis, 2000; Volk et al., groups, when compared to the expression pattern of all
detectable transcripts, were not significantly different2000). In addition, the clinical heterogeneity of schizo-
phrenia probably reflects a complex biological sub- (p . 0.05) between the schizophrenic and control sub-
jects (Figures 1E–1H), establishing that other changesstrate, but with key elements that are common to the
clinical phenotype. Consequently, in order to determine that we did detect are not due simply to human subject
variability. This observation also is in agreement withwhether there are modest, but consistent, changes in
gene expression in the PFC across schizophrenic sub- previous findings that total mRNA levels in schizophrenic
subjects are comparable to those in the unaffected hu-jects, we designed a three-step experimental approach.
First, we used high-density cDNA microarrays (Brown man population (Harrison et al., 1997). However, several
gene groups exhibited significantly changed expressionand Botstein, 1999; Duggan et al., 1999; Whitney et al.,
1999; Alizadeh et al., 2000) to compare the relative levels in schizophrenic subjects, both within individual pairs
and across pairs (presynaptic secretory machinery,of over 7000 gene transcripts in the PFC of matched
pairs of schizophrenic and control subjects. These data GABA transmission, glutamate transmission, energy
metabolism, growth factors, and receptors).were analyzed by gene expression profiling of over 250
gene groups, including custom-designed cascades of In particular, transcript levels were significantly de-
creased in the schizophrenic subjects for a group ofgene products related to specific nervous system func-
tions. Following hierarchical analysis of these data, we genes that were functionally related to the presynaptic
secretory machinery (PSYN) (Figure 1B). Expression ofverified selected microarray findings using in situ hybrid-
ization. Finally, we determined whether the most signifi- genes involved in glutamate and GABA neurotransmis-
sion (Figures 1C and 1D) were also decreased, support-cant differences in gene expression also were present in
a second cohort of schizophrenic and control subjects. ing previous studies that have documented changes of
individual genes within these latter groups in the PFC
of schizophrenic subjects (Collinge and Curtis, 1991;Results
Harrison et al., 1991; Akbarian et al., 1995b, 1995c, 1996;
Chen et al., 1998; Volk et al., 2000). For example, theMicroarrays Reveal Defects in Expression
microarrays reported decreased glutamic acid decar-of Synaptic Function–Related Gene Groups
boxylase 1–67 kDa (GAD67) expression, essentially re-We performed several control experiments to assess the
producing our previous study of in situ hybridizationfeasibility of microarray analysis on postmortem human
(Volk et al., 2000) on the same subjects with schizophre-brain tissue. First, we hybridized two aliquots of the
nia. Furthermore, less consistently reported changes insame cortical Cy3- and Cy5-labeled mRNA from a con-
glutamate receptor 1 and 2 (AMPA1–2, GluR1–2) expres-trol subject onto one UniGEM-V cDNA array (Figure 1A).
sion in other cortical regions (Eastwood et al., 1995,The obtained data showed a normal distribution with
1997) were also reproduced. It is possible that the defi-variability that was in agreement with Incyte’s extensive
cits in these systems observed in the present study mayUniGEM-V reproducibility studies (http://www.incyte.com/
be related to the changes in the presynaptic secretorygem/technology/GEM-reproducibility.pdf). Second, to
machinery transcripts. However, the limited number ofassess interexperimental variability, pair 685c/622s was
microarray targets related to these specific neurotrans-hybridized to three different UniGEM-V microarrays. The
mitter systems hindered our ability to further interpretresults obtained in the three experiments were consis-
these observations. Furthermore, we were not able totent and reported the same changes in gene expression
fully assess changes in a number of other neurotransmit-between the schizophrenic and control subject (data
ter systems (e.g., dopamine, norepinephrine, serotonin)not shown). These control data indicated that microarray
due to the low number of transcripts related to theseanalysis is a reliable tool for analyzing gene expression
systems on the microarrays.changes in human postmortem brain tissue.
Next, using high-density cDNA microarrays, we ana-
lyzed global gene expression in PFC area 9 from six The Expression of the PSYN Gene Group
Is Decreased in the PFCs of Allmatched pairs of schizophrenic and control subjects.
Of all genes and expressed sequence tags (ESTs) inter- Schizophrenic Subjects
We focused our attention on what appeared to be therogated by the six microarrays, an average of 3735 (SD 5
1345) gene transcripts per array were detectable in the most robustly affected functional group, those genes
related to the PSYN cascade. Although this group pri-pairwise comparisons. Of these transcripts, 4.8% were
judged to be differentially expressed within a subject marily includes transcripts encoding presynaptic secre-
tory machinery proteins, a substantial number of thesepair based on the stringent criterion of having $j1.9j-
fold difference (99% confidence level [CL]) between sub- gene products are also involved in other cellular func-
tions, mostly related to membrane trafficking. Acrossjects in fluorescent signal intensity. The observed differ-
ences for any subject pair, in general, were comparably the six microarray comparisons, of the 62 genes repre-
sented in the PSYN group, on average 41 PSYN genesdistributed in both directions: 2.6% of the genes were
expressed at higher levels in schizophrenic subjects products were detectable in the subject pairs. Schizo-
phrenic subjects differed in the number of genes in thethan in the matched controls, whereas 2.2% were ex-
pressed at lower levels in the schizophrenic subjects. PSYN group that were decreased over the 95% confi-
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Figure 1. Gene Expression Differences in PFC Area 9 for Six Pairs of Schizophrenic and Control Subjects as Revealed by Microarray Analysis
For each gene group, all expressed genes were classified into signal intensity difference intervals (0.1 bins) according to their Cy5/Cy3 signal
ratio. Transcripts in a “1” bin had identical Cy5 versus Cy3 signal intensities. Positive values (to the right) on the x axis denote higher Cy5
signal in schizophrenic subjects (S . C), negative values (to the left) correspond to higher Cy3 signal intensity in the control subjects (C .
S). The y axis reports the percentage of expressed genes across the six subject pairs per bin for each gene group. In all panels, the white
bars (all genes) denote distribution of all expressed genes across the six PFC pairwise comparisons (n 5 22,408).
(A) Hybridization of two aliquots of the same cortical mRNA from one control subject (all genes control). One aliquot of control cortical mRNA
was labeled with Cy3, the other with Cy5, and the combined sample was hybridized onto a single UniGEM-V cDNA microarray. At the 99%
confidence level ($j1.9j), only four of the 4844 expressed genes (0.08%) reported a false positive Cy5 bias, and two genes (0.04%) reported
a false positive Cy3 bias. In contrast with this control experiment, 4.8% of all expressed genes in the six combined PFC comparisons showed
a differential expression over the 99% confidence level. Of all expressed genes in the six combined PFC comparisons, 95% of the expressed
genes reported Cy3/Cy5 signal intensity ratios #j1.6j.
(B–H) Distribution of expressed genes for transcripts related to PSYN group (B), glutamate system (C), GABA system (D), glial markers (E),
adhesion molecules (F), cytokines (G), and proteases (H). Note that genes classified in the PSYN group, glutamate system, and GABA system
groups exhibit a pronounced decrease (shift to the left) in transcript expression in the schizophrenic subjects. Statistical tests of this leftward
shift are noted in Table 1.
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dence level (Figure 2A). For each of the six comparisons,
between 6 and 26 genes were changed (13.3%–56.9% of
expressed PSYN genes). Furthermore, when combined,
out of the total of 246 PSYN group observations, 17.9%
of genes showed a decrease at the 99% CL (#21.9),
and 29.3% showed a significant decrease at the 95%
CL (#21.6) in the schizophrenic subjects across the
six pairwise comparisons (Table 1A). This shift in the
distribution of the PSYN genes was present in all sub-
jects, and it was highly significant for both the individual
comparisons and at the level of the combined data (p ,
0.0001). This highly skewed distribution of the PSYN
gene group was not due to individual variability between
subjects, because individual random variability must oc-
cur in both directions. At the 99% CL, 2.2% of all genes
were underexpressed in the schizophrenic subjects,
suggesting that less than one PSYN gene per subject
would be decreased due to the to individual variability
(41 expressed genes 3 0.022 5 1 gene for a single
comparison or 246 3 0.022 5 5.5 genes across all six
pairs). Furthermore, in a random distribution, at least
six PSYN genes would be expected to show increased
expression across the six schizophrenic subjects (246 3
0.028). However, this was not the case for the genes
in the PSYN group. Over the 99% CL across the six
schizophrenic subjects, only one (0.4%) PSYN gene re-
ported an increase, and 44 (17.9%) PSYN transcripts
were decreased. In addition, at the 95% CL we observed
only 2 (0.8%) increased and 72 (29.3%) decreased PSYN
genes across all the schizophrenic subjects.
In addition to the frequency distribution data, central
tendency measurements also revealed a 38% decrease
(21.48-fold) (p , 0.005) of all expressed genes in the
PSYN group compared to the average expression of all
genes (21.10) (Table 1B). Removing either the two most
consistently changed PSYN genes (N-ethylmaleimide
sensitive factor [NSF] and synapsin II [SYN2]), or the
two most affected schizophrenic subjects, did not elimi-
nate the significance of the findings (Table 2). The PSYN
Figure 2. The PSYN Group Changes Consistently in Each Schizo- group average, without NSF and SYN2, still showed a
phrenic Subject 33% decrease (21.43-fold) (p 5 0.004) in comparison
Pairs of control and schizophrenic subjects (“c” and “s” following to the mean of all expressed genes (21.10). These data
subject number, respectively) are denoted in all figures in closed indicate that many different genes contributed to the
boxes.
consistent transcript decrease of the PSYN group, in-(A) Each graph represents a single microarray experiment, with the
cluding those genes whose expression did not reachlayout the same as in Figure 1B. Histogram bars represent distribu-
tion of expressed genes as a function of Cy5/Cy3 signal ratio. Blue the expression level difference of #21.6.
bars denote distribution of PSYN group. Yellow bars denote distribu-
tion of all expressed genes within the same microarray comparison. PSYN Gene Expression Deficits Are Different
Black arrows denote “1” bin (identical Cy3/Cy5 signal intensity). between Schizophrenic Subjects
Green arrowheads depict 95% and red arrowheads denote 99%
The hierarchical data analysis revealed an unexpectedconfidence interval (CL) of transcript decrease, respectively. The
aspect of altered gene expression. The specific membersshift to the left in the distribution of the PSYN group was highly
significant (p , 0.001) in each individual microarray comparison. of the PSYN gene group showing decreased expres-
(B) Expression differences for six genes related to synaptic machin- sion, and the relative magnitude of individual transcript
ery and one gene each for the glutamate and GABA systems in changes, differed across the pairwise comparisons (Figure
six microarray experiments. The six PSYN genes were chosen to 2B), revealing different patterns of decreased gene ex-
represent three consistently changed genes (NSF, SYN2, and
pression in the schizophrenic subjects. However, whileATPase) and three occasionally changed genes (STAG5, SJAN1,
individual differences across subject pairs can be inter-and SGYR1). Y axis denotes expression differences between control
and schizophrenic subjects measured by percent of Cy5/Cy3 inten-
sity. Red dashed line represents a transcript decrease of 47.5%
(99% CL), green dashed line corresponds to 37.5% decrease trend
(95% CL), black dashed line denotes equal Cy5/Cy3 signal (0% STAG5, synaptotagmin 5; SGYR1, synaptogyrin 1; ATPase, vacuolar
change). Note that the pattern of decrease in PSYN transcripts dif- proton pump (42 kDa); GAD67, glutamic acid decarboxylase 1 (67
fers across schizophrenic subjects. Abbreviations: NSF, N-ethylma- kDa); and AMPA2, glutamate receptor 2 (AMPA2, GLUR2, GLURB,
leimide sensitive factor; SYN2, synapsin II; SJAN1, synaptojanin 1; GRIA2).
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Table 1. Summary Statistics of Gene Group Data Observed by Microarrays
Distribution of Expressed Genes across Six PFC Comparisons
A. (22408) (246) (46) (88) (88) (119) (178) (425)
Percent of Change ALL PSYN GLU GABA GLIAL ADH CYT PROT
.1.9 2.6 0.4 0.0 0.0 5.7 4.2 5.6 2.1
1.6 to 1.89 2.8 0.4 0.0 4.5 3.4 3.4 3.4 2.6
21.59 to 11.59 86.7 69.9 65.2 70.5 83.0 81.5 83.7 87.3
21.6 to 21.89 5.7 11.4 17.4 12.5 3.4 7.6 5.1 6.6
,21.9 2.2 17.9 17.4 12.5 4.5 3.4 2.2 1.4
Chi-square, p , NA 0.0001* 0.0001* 0.0001* 0.12 0.63 0.43 0.97
Average of Expressed Genes across Six PFC Comparisons
(.7,000) (62) (11) (18) (22) (37) (82) (240)
B. ALL PSYN GLU GABA GLIAL ADH CYT PROT
Mean number of expressed genes 3735 41.0 7.7 14.7 14.7 19.8 29.7 70.8
6 SD 1344 8.76 1.97 3.72 4.32 6.79 7.66 25.37
Mean expression ratio 21.10 21.48 21.42 21.36 1.09 21.06 1.01 21.04
6SD 0.05 0.27 0.10 0.14 0.52 0.06 0.10 0.12
t test (df 5 5), p , NA 0.005* 0.001* 0.002* 0.222 0.216 0.065 0.221
Data analysis was performed across all six pairs of schizophrenic and control subjects. ALL, all expressed genes; PSYN, presynaptic secretory
machinery; GLU, glutamate system; GABA, GABA system; GLIAL, glial markers; ADH, adhesion molecules; CYT, cytokines; PROT, proteases.
(A) Chi-square was calculated against all expressed genes in the six PFC comparisons. The total number of expressed gene observations
across the six microarrays is given in parenthesis above each gene group. Note that transcript decreases in the PSYN, GLU, and GABA
groups in schizophrenic subjects were highly significant (p # 0.0001) by comparing distribution of expressed ratios.
(B) Mean expression ratios (average of six mean expressions) for each gene group were calculated across the six microarray comparisons.
The mean expression ratio for each gene group was compared to the mean expression ratio of all expressed genes using a t test (df 5 5).
Numbers in parentheses denote number of genes that comprise each gene group. Note that transcript decreases in the PSYN, GLU, and
GABA groups in schizophrenic subjects were significant (p # 0.005) by comparing distribution of expressed ratios.
preted as a result of different patterns of decreased by 26%–74% and 17%–79%, respectively, in the six
schizophrenic subjects (Figure 2B). To verify the mi-PSYN gene expression across the schizophrenic sub-
jects, some of the observed individual pattern changes croarray findings for these genes, and for two others that
exhibited modest changes and only in a few subjectsalso could be due to the pairwise experimental design
and the comparison of each schizophrenic subject to a (synaptojanin 1 [SJAN1] and synaptotagmin 5 [STAG5]),
we performed in situ hybridization for five of the samedifferent, matched control. Consequently, we tested the
later interpretation in a post hoc manner using the in subject pairs used for the microarray experiments. For
pair 794c/665s, no sections were available from thesitu hybridization data (see below).
Within the PSYN group, the two most consistently same block of tissue used in the microarray experiment.
Radiolabeled cRNA probes specific for NSF, SYN2,altered gene products, NSF and SYN2, were decreased
Table 2. PSYN Central Tendency Measures with and without Selected Genes and Distribution Classes
Expressed PSYN Genes
Pairs/MEAN
Expression All Expressed Genes All w/o NSF & SYN2 w/o ,21.9 & .1.9 w/o ,21.6 & .1.6
H558c/H317s 21.19 21.90 21.82 21.25 21.20
H516c/H547s 21.10 21.71 21.60 21.21 21.08
H604c/H581s 21.09 21.27 21.26 21.22 21.18
H630c/H566s 21.07 21.25 21.22 21.20 21.15
H685c/H622s 21.09 21.41 21.38 21.31 21.28
H794c/H665s 21.04 21.34 21.31 21.28 21.19
Average of means 21.10 21.48 21.43 21.24 21.18
SD 0.05 0.27 0.23 0.04 0.07
t test (df 5 5) p , NA 0.005 0.004 0.001 0.025
PSYN Frequency Distribution with and without NSF and SYN2
All Expressed Genes Expressed Genes—PSYN PSYN w/o NSF and SYN2
Category Number of Genes Percent Number of Genes Percent Number of Genes Percent
.1.9 576 2.6 1 0.4 1 0.4
1.6 to 1.89 629 2.8 1 0.4 1 0.4
21.59 to 11.59 19426 86.7 172 69.9 169 72.2
21.6 to 21.89 1278 5.7 28 11.4 26 11.1
,21.9 499 2.2 44 17.9 37 15.8
TOTAL 22408 100 246 100 234 100
Chi-square p , NA 0.0001 0.0001
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Figure 3. PFC Expression of Two Consistently Changed PSYN Genes (NSF and SYN2) and Two Occasionally Changed Genes (SJAN1 and
STAG5)
The in situ hybridization data from ten PFC pairwise comparisons were quantified using film densitometry. X axis represents ten pairwise
comparisons, Y axis reports corrected film optical density measured across all layers for each control and schizophrenic subject. Lines
connecting symbols indicate a matched subject pair. Note that NSF (A) and SYN2 (B), both consistently decreased across the initial six
microarray comparisons were also significantly decreased across the ten in situ pairwise comparisons. However, as expected, the two
occasionally changed genes in the microarray comparisons, STAG5 (C) and SJAN1 (D), showed inconsistent changes that were marginally
significant (indicated in boxes) between the control and schizophrenic subjects.
SJAN1, and STAG5 were used to localize and quantify and STAG5 changes reported by the microarrays would
be altered to a lesser degree only in a subset of schizo-relative transcript levels. The in situ hybridization experi-
ments confirmed the microarray findings for the schizo- phrenic subjects. Indeed, from the second set of pairs,
for both STAG5 and SJAN1, only one of five compari-phrenic subjects (Figures 2B, 3, and 4). At the group
level, the decreases determined by microarray and in sons exhibited a .20% decrease (Figures 3C and 3D).
Across the ten pairs, due to less consistent decreasessitu hybridization experiments were highly correlated
(r 5 0.70; p , 0.001). in expression, overall STAG5 and SJAN1 expression
levels were only marginally changed (216.2%, p 5 0.05,Our findings also suggested that the most consistently
observed decreases in transcripts across the microarray and 214.2%, p 5 0.04, respectively).
To test if the apparently distinct patterns of decreaseexperiments (e.g., NSF and SYN2) would reproduce by
in situ hybridization in a different cohort of schizophrenic of the PSYN group in individual schizophrenic subjects
are present for the NSF, SYN2, STAG5, and SJAN1subjects. To test this prediction, we examined whether
NSF and SYN2, the most affected PSYN transcripts in genes, we analyzed the in situ hybridization data post
hoc in an unpaired experimental design. The correctedthe six original subject pairs, were also altered in a differ-
ent cohort of five matched pairs of schizophrenic and OD values, obtained for each schizophrenic subject,
were compared to the mean OD values for each of thecontrol subjects. Indeed, in these additional compari-
sons NSF transcript levels were decreased in all five ten control subjects, as well as to the overall average
OD values of the ten control subjects (Figure 5). Acrossschizophrenic subjects, and SYN2 levels were de-
creased in four of five schizophrenic subjects. Across the ten schizophrenic subjects, at least four different
patterns of decreased expression of NSF, SYN2, STAG5,all ten subject pairs, the mean levels of NSF and SYN2
expression were significantly decreased in the schizo- and SJAN1 genes emerged, regardless of control sub-
ject used for comparison. The patterns of decreasedphrenic subjects by 40% (p , 0.001) and 37% (p ,
0.005), respectively (Figures 3A and 3B). In contrast, we expression also were present when single schizophrenic
subjects were compared to the pooled, “reference” con-predicted that the occasional and more modest SJAN1
Gene Expression in Schizophrenia
59
nosis was no longer significant. In addition, for each of
the four genes, no differences in gene expression were
observed between the schizophrenic subjects with (n 5
4) or without (n 5 6) a history of substance abuse, or
between those with a diagnosis of schizoaffective disor-
der (n 5 3) or “pure” schizophrenia (n 5 7).
Decreased PSYN Expression Is Not Induced
by Antipsychotic Treatment
Two subjects with schizophrenia were not receiving anti-
psychotic medications at the time of death (622s and
547s), and both showed decreased expression of the
PSYN group. As an additional strategy to address the
influence of chronic exposure to antipsychotic medica-
tions (Nakahara et al., 1998; Johnson et al., 1999; Sele-
mon et al., 1999), we compared gene expression in the
frontal cortex of haloperidol-treated and control mon-
keys by microarray and in situ hybridization analyses.
In one such pairwise comparison on a cDNA microarray,
chronic haloperidol treatment produced changes in
gene expression, but none of these were related to the
PSYN group (Figures 6A and 6B), or to the glutamate and
GABA systems (data not shown). In situ hybridization
analysis of NSF, SYN2, STAG5, and SJAN1 in two
matched pairs of haloperidol-treated and control ani-
mals also failed to detect any decreases in expression
(Figures 6B and 6C). Although the effects of chronic
antipsychotic medication on PSYN gene expression
cannot be completely excluded, evidence from both hu-
man and monkey studies suggests that the observed
alterations in the expression of PSYN genes reflect the
pathophysiology of schizophrenia and not treatment
with antipsychotic medications. Indeed, our previous
investigations have confirmed the utility of this com-
bined approach by demonstrating that certain gene
products in the PFC were increased, rather than de-
creased, both in schizophrenic subjects receiving anti-
Figure 4. In Situ Verification of UniGEM-V Data for NSF and SYN2
psychotic medication relative to schizophrenic subjects
Dark-field photomicrographs of PFC tissue sections from matched
not receiving antipsychotic medication at the time ofpairs of control and schizophrenic subjects (denoted by “c” and “s”
death and in haloperidol-treated monkeys relative tofollowing subject number, respectively). Complete set of micro-
control monkeys (Lewis, 2000).graphs for each gene was taken under identical illumination condi-
tions at 253 magnification. Pial surface is towards the top of each
image. Numbers denote percentage of transcript decrease in Discussion
schizophrenic subjects as reported by the OD measurements of
X-ray film (black numbers) and by microarray analysis of same pairs
This study of a complex psychiatric disease combines(red numbers).
the power of initial data acquisition from high-density
cDNA microarrays, function-related data mining, and
conventional molecular biology techniques to confirmtrol. The variation patterns observed by in situ hybridiza-
findings for individual genes. Our finding of a deficit intion for these four genes are highly suggestive that dis-
the expression of genes encoding functionally definedtinct patterns of PSYN gene decreases seen on the
cascades of proteins underscores the utility of microar-microarrays are characteristic for subjects with schizo-
rays as screening tools for complex changes in genephrenia.
expression patterns in psychiatric diseases.
Decreased PSYN Gene Expression Is Not
a Result of Confounds Reduced Expression of Genes Related to the
Presynaptic Secretory MachineryFor each gene examined by in situ hybridization, group
differences in OD measurements were examined using The number of PFC neurons appears to be normal in
schizophrenia, and thus loss of neurons cannot accountanalysis of covariance (ANCOVA) with diagnosis as the
main effect and sex, age, postmortem interval, brain pH, for our findings (Pakkenberg, 1993). Furthermore, through
our statistical analysis, we demonstrate that the reducedand tissue storage time as covariates. These potential
confounds did not account for the observed changes expression of PSYN genes is related to the disease pro-
cess of schizophrenia and not a consequence of itsin the schizophrenic subjects, except for STAG5, where
at group level, in an unpaired design, the effect of diag- treatment or a confound of subject characteristics. At
Neuron
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Figure 5. Individual and Distinct NSF, SYN2, SJAN1, and STAG5 Gene Expression Patterns in Schizophrenic Subjects
OD comparison of in situ hybridization data between schizophrenic subjects 317s (A), 547s (B), 566s (C), 622s (D) and individual control
subjects. Y axis reports NSF, SYN2, STAG5, and SJAN1 expression changes compared to each control subject and the average of the control
subjects on the x axis (AVG). Note the distinct gene expression patters in these four subjects (boxes).
the 99% CL, 4.5%–54% of the expressed genes in the schizophrenic subjects without marked individual differ-
ences. Furthermore, general synapse loss should pro-PSYN group were decreased in each schizophrenic sub-
ject, but the specific genes affected differed across sub- duce comparable decreases across all synaptic machin-
ery transcripts within a single brain comparison. This didjects. Although some of the less consistent and moder-
ate changes cannot be ruled out as contributing to the not occur in any of the microarray pairwise comparisons:
some transcripts encoding presynaptic markers were al-differences in individual expression profiles, the data
suggest that, at least in part, our findings are not due ways unchanged (e.g., syntaxin 1), some were occasion-
ally changed (e.g., synaptogyrin 1, SJAN1, STAG5), andto a generic loss of neuropil. Such a loss would be
expected to affect gene expression similarly in all others were consistently changed (e.g., NSF, SYN2, and
Figure 6. Chronic Haloperidol Treatment Does Not Decrease Expression of PSYN-Related Genes in Cynomolgus Monkeys
(A) Microarray hybridization data from the PFC of a haloperidol treated (206h) and matched control (205c) monkey. Figure layout is the same
as in Figure 1B. h, haloperidol treated; c, matched control.
(B) Expression changes for one microarray (206h/205c) and two in situ pairwise comparisons (206h/205c and 208h/207c) for NSF, SYN2,
SJAN1, and STAG5. Figure layout is the same as in Figures 2B and 2C.
(C) In situ hybridization micrographs from the dorsal PFC of a haloperidol-treated (206h) and matched control (205c) monkey viewed under
dark-field microscopy at 253 magnification. Pial surface is toward the top of each image. Numbers denote percent differences reported by
in situ (black) or microarray (red) analysis.
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vacuolar proton pump-42 kDa [ATPase]). In addition, a classic neurofibrillary tangle pathology. However, just
as decreased expression of all genes in the PSYN groupprevious analysis in the same pairs of subjects used in
the present study, showed that the number of neurons was not present in each schizophrenic subject, alter-
ations in one particular chromosomal locus are not likelyexpressing synaptophysin 1 mRNA, and the level of ex-
pression per neuron, did not differ between schizo- to be present in all schizophrenic subjects.
phrenic and control subjects (Glantz et al., 2000). Thus,
we propose that subjects with schizophrenia share a Schizophrenia as a Deficit of a Final Common Path
common abnormality in the control of presynaptic func- of Conserved Functional Abnormalities
tion in the PFC but that they may differ in terms of Our results suggest that schizophrenia may be caused
the specific combination of genes that exhibit reduced by multigene defects that lead to a final common path of
levels of expression. This latter possibility is supported conserved functional abnormalities. For disorders other
by the in situ hybridization results, in which variations than schizophrenia, single or multigene defects in differ-
in the decrease patterns for NSF, SYN2, STAG5, and ent members of a functional cascade have been shown
SJAN1 were evident in some schizophrenic subjects, to produce the same disease with virtually indistinguish-
regardless of the control subject used for comparison. able symptoms. For example, over 70 gene loci or genes
As part of the overall deficit in expression of the PSYN have been implicated in the pathogenesis of retinitis
gene group in schizophrenic subjects, we also report a pigmentosa (Inglehearn, 1998; van Soest et al., 1999).
significant and consistent decrease in expression of In addition, first episode, never-medicated, and chroni-
NSF, SYN2, and ATPase in subjects with schizophrenia. cally ill schizophrenic subjects exhibit similar changes
For NSF and SYN2, in which in situ analysis also was in functional and structural imaging studies of the PFC,
done, these deficits were evident using both paired and and thus the deficits in PSYN gene expression are likely
unpaired comparisons. Alterations in transcripts for these to contribute to PFC dysfunction at all stages of the
genes have not been reported previously in schizophre- illness (Pettegrew et al., 1993; Stanley et al., 1996; Har-
nia and could be central to the pathogenesis of the rison, 1999).
disorder. Alternatively, NSF, SYN2, and ATPase tran-
scripts may simply be particularly sensitive to deficits A Testable Model of Schizophrenia
in other genes related to overall synaptic function. In The preponderance of data in the literature still reflects
addition, we wish to emphasize that other synapse- a lack of credible evidence of a specific biological mech-
related genes, not yet identified, also may be consis- anism being responsible for schizophrenia and its ex-
tently decreased in schizophrenia. pressed symptoms (Weinberger, 1999). We know that
Many synaptic proteins also play a role in membrane the essence of the disease has a complex neurobiologi-
trafficking. Consequently, PSYN group gene changes, cal basis, influenced by both polygenic, non-Medelian
in addition to reflecting potential alterations in synaptic inherited genetic variation and epigenetic factors (Risch
release, also may affect overall protein trafficking. Pre- and Baron, 1984).
synaptic secretory function, however, is likely to be a Toward which directions of future investigations can
principal target of altered PSYN gene expression. For the present microarray analysis point us regarding falsi-
example, the Drosophila mutant comatose, deficient in fiable models of the disease? We put forth a model
the widely expressed and multifunctional NSF gene, ex- with four important components that address issues of
hibits a primary defect in maintaining a readily releasable genetic susceptibility, developmental time course, and
pool of synaptic vesicles (Tolar and Pallanck, 1998). synaptic dysfunction that underlie the pathophysiology
of schizophrenia.
The Etiology of Schizophrenia Involves a PolygenicMultigene PSYN Deficits Link
to Schizophrenic Loci Pattern of Inheritance that Results in Altered
Function of Proteins Controlling theOur hypothesis that schizophrenia is a disorder of a
functionally related group of genes is consistent with a “Mechanics” of Synaptic Transmission
Several PSYN genes and/or gene products already hadmultiloci pattern of linkage. Indeed, loci 22q11-13,
17q21, 1q21.3, 3p24-26, and 5q12-q13 have each been been shown by conventional methods to be decreased
in schizophrenia (Browning et al., 1993; Tcherepanovimplicated in schizophrenia (Bird et al., 1997; Kara-
yiorgou and Gogos, 1997; Pulver, 2000; Tsuang, 2000) and Sokolov, 1997; Harrison and Eastwood, 1998; Da-
vidsson et al., 1999; Karson et al., 1999). The present(http://www.ncbi.nlm.nih.gov/htbin-post/Omim/
dispmim?181500#MAPPING) and contain genes encod- results, however, highlight what we believe to be a key
feature of gene expression that only could have beening proteins related to PSYN genes or synaptic function.
In fact, there are clear indications that alterations at ascertained by a high throughput genomics approach,
in which dozens of genes in multiple molecular cascadessome of these loci may be involved in the primary patho-
physiology of schizophrenia. For example, deletions in are profiled simultaneously, without a constraining hy-
pothesis or a need for robust linkage to a particularthe 22q11-12 region, encoding numerous synapse-
related genes, have been associated with a prevalence locus. In the present report, we show that the particular
altered transcripts in the PSYN cascade, and the extentof schizophrenia that is 25-fold greater than the general
population (Murphy et al., 1999). Furthermore, a linkage to which they change, varies among subjects, but with
consistency in a small number of “most affected” genes.study with a logarithm of odds score of 5.0 on chromo-
some 17q21 (containing, among others, the NSF and This fits with polygenic, non-Mendelian inherited disor-
ders, in which independent studies produce maximalATPase genes) has been linked (Bird et al., 1997) to
the development of schizophrenia-like symptoms and evidence for linkage at different loci, but with examples
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of common alleles that have sufficiently large effects to II gene, expression levels for many (but not all) of the
be detected (Risch, 2000). Our model encompasses the other genes in the PSYN group are decreased (Rosahl
scenario that mutations/polymorphisms in one or sev- et al., 1995), though to varying degrees. In addition,
eral of these genes, which may result in dysregulated mice lacking synapsin I (Rosahl et al., 1995), synapsin
expression of normal gene products, are sufficient to II (Rosahl et al., 1995), SCAMP1 (Fernandez-Chacon et
lead to a final common path of conserved functional al., 1999), synaptophysin I, synaptogyrin 1 (Janz et al.,
abnormalities. Risch (2000) suggests that this polygenic 1999), or Rab3a (Jahn and Sudhof, 1999) are viable and
view of the inherited component of schizophrenia can lack gross functional deficits, but display impairments
be tackled more effectively using a forward genetics in repetitive synaptic release and synaptic plasticity,
approach. Using leads from our and future microarray while synaptotagmin IV–deficient mice show impaired
studies that would probe the PSYN group more com- learning and memory (Ferguson et al., 2000).
pletely, a forward genetics approach would embrace a Deficits in PSYN Gene Expression Are Linked
prioritized search for single nucleotide polymorphisms to the Neurodevelopmental Time Course
(SNPs) that, depending upon their location in coding or of Schizophrenia
regulatory regions, could effect PSYN gene expression How might this occur? The extended period of synapto-
and function. The ability to narrow the SNP search from genesis and pruning, from just before birth through ado-
the hundreds of thousands of possibilities is clearly a lescence in the primate cerebral cortex, is perhaps the
major advantage for defining disease associations. Us- most susceptible component of development to epige-
ing the growing human genome and SNP databases, we netic factors that can influence both the molecular adap-
can design novel “sequencing,” protein and expression tation of PSYN gene expression and subsequent neu-
arrays to more fully characterize the underlying molecu- ronal function. Thus, alterations in synaptic efficacy will
lar mechanism of schizophrenia. We suggest that across have an impact on the organization and refinement of
schizophrenic subjects altered gene expression pat- circuits during the experience-expectant and -depen-
terns will sort into a continuum related to the variations dent phases of synaptic development. For example,
across individuals in clinical features. Thus, SNPs and phase 4 of synaptic development corresponds to the
gene expression patterns could be predictive of the age period when net synapse number is stable, from early
of onset, severity of illness, and, ultimately, of the most youth to prepuberty (Bourgeois, 2001). During this time,
effective treatments. however, normal synapse reorganization occurs (e.g.,
The Heterogeneity in Expression Defects within the balance of synapses on spines versus shafts) with-
the PSYN Group Is a Reflection of Distinct out a change in synapse number. In the primate, altered
Adaptive Capacities of Different visual experience has a pronounced negative impact on
Populations of Neurons the balance of spine and shaft synapses that are formed
In our model, a modest number of susceptibility genes, in visual cortex (Bourgeois, 2001). Phase 5 of synaptic
including PSYN or postsynaptic components (such as development, initiated around puberty in monkey and
G protein–coupled signaling), would be primarily dys- human (Bourgeois et al., 1994; Huttenlocher and Dab-
functional and would lead to phenotypic adaptations, holkar, 1997), includes the period of synaptic pruning,
which in some individuals would present clinically. This in which a normal elimination of 30%–40% of synapses
aspect of the model requires heterogeneous expression leads to a stable adult complement. Experimentally, al-
of PSYN genes across different neuronal types and brain tered synaptic function in the cortex, tested by eye re-
areas, otherwise widespread peripheral and central neu- moval in the embryonic monkey to alter visual experi-
ral dysfunction, incompatible with life would occur. Al- ence (Bourgeois, 2001), leads to dramatic changes in
though surprisingly understudied, a few reports in the the rate and type of synapses that are lost, but still
literature document that such heterogeneity exists in results in a near normal number of total synapses in the
rodents (Melloni et al., 1993; Matus-Leibovitch et al.,
neuropil. Though somewhat far-reaching, we suggest in
1997; Porton et al., 1999), but detailed analysis is needed
our model that PSYN dysregulation gives rise to a
in primate brain. The added feature of adaptive capaci-
“catch-22 scenario” for specific neural circuits, in whichties of different neurons leads directly to the hypothesis
subclinical synaptic dysfunction during adolescencethat some circuits naturally will be more susceptible to
and puberty, due in part to defects in PSYN gene expres-functional disruption than others. This is readily testable
sion, leads to maladaptive mechanisms for synaptic sta-in forward genetic studies in which mutations are cre-
bilization and circuit function. Given our hypothesis thatated conditionally, both spatially and temporally, provid-
neuronal dysfunction is dependent on the expressioning a substrate for analysis of predictable molecular
of the altered PSYN susceptibility genes, certain devel-adaptations and physiological consequences. Few of
oping circuits will be affected in a more pronouncedthese experiments have been performed, but recent re-
fashion than others. A falsifiable experiment would in-ports provide evidence for complex and not necessarily
corporate the use of additional microarray data to definepredictable changes in synaptic plasticity and molecular
adaptive PSYN gene expression patterns, which will helpadaptations. Indeed, studies of mice with deletions of
investigators create appropriate genetic hypomorphs orindividual synapse-related genes indicate that single ge-
conditional mutants, with subsequent analysis of thenetic abnormalities can affect the transcription levels of
formation and pruning of synapses. The prediction in-a functionally defined gene group. For example, deletion
cludes, of course, a postpubertal onset of behavioralof synapsin I results in major decreases in the expres-
dysfunction that can be tested in standard assays. Thesion of synaptic vesicle proteins and acceleration of
expression of pronounced behavioral disturbances, ap-synaptic depression, but no change in LTP (Rosahl et
al., 1995). Furthermore, in mice deficient in the synapsin pearing postpubertally and with a neurodevelopmental
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clinical records, toxicology studies and structured interviews withetiology, have been described recently in genetic (Bur-
surviving relatives as previously described (Pierri et al., 1999). Tenrows et al., 2000) and lesion models (Wood et al., 1997).
of the schizophrenic subjects had been used in a previous study ofDeficits in PSYN Expression Have Physiological
GAD67 mRNA expression in PFC area 9 (Volk et al., 2000).
and Behavioral Consequences Relevant to
the Pathophysiology of Schizophrenia Human Postmortem Tissue Preparation
In the context of reduced expression or mutation of The cause of death and the pH of the brain tissue suggested a short
agonal state in all subjects, indicating that the brain tissue wasmultiple PSYN genes, neurons will have an impaired
appropriate for use in microarray experiments (Barton et al., 1993).release of synaptic vesicles at nerve terminals. Such
Fresh-frozen human tissue was obtained from the University of Pitts-deficiencies may not be particularly meaningful under
burgh’s Center for the Neuroscience of Mental Disorders Brain Bankconditions of low synaptic activity but would have dire
and area 9 from the right hemisphere was identified as previously
functional consequences when either high rates of sus- described (Glantz and Lewis, 2000; Volk et al., 2000). For microarray
tained or synchronous firing are required. Indeed, mice analysis, cryostat sections (30–50 mm) were collected into 50 ml
tubes at 2248C under nuclease-free conditions, providing 300–900deficient in different PSYN genes do display deficits in
mg of wet weight per specimen. Total RNA was extracted usingsustained release and in long-term potentiation (Rosahl
Promega kit #Z5110, with modification. Total RNA yields were 0.2%–et al., 1995; Fernandez-Chacon et al., 1999; Jahn and
0.8% of the wet tissue weight with an OD260/280 over 1.70. The mRNASudhof, 1999; Janz et al., 1999). The situation in schizo-
was extracted by Qiagen kit #70022. Typical yields for mRNA were
phrenia is obviously more complex, but multiple defects about 0.1%–0.5% of the total RNA with an OD260/280 of over 1.80. The
in PSYN genes could cause deficiencies in the ability volume was adjusted using Microcon columns YM-30 #42,409 to
50 ng/ml. The integrity of the isolated material was comparable toto maintain sustained firing or synchronize firing within
those seen in rat brains with a 2–3 min PMI (our unpublished data).certain cortical and subcortical networks. Such a mech-
anism could underlie the consistent finding that subjects
Experimental Designwith schizophrenia show less activation of PFC during
We used a matched sample design, in which each of the schizo-tasks that require the sustained neural activity involved
phrenic samples was compared to a matched control on each of
in working memory. Indeed, considerable evidence from the microarrays. There were two principal reasons for using this
human and monkey studies indicate that disturbances design.
First, aging is known to affect gene expression levels in the brainor interruptions in sustained neural activity of the PFC
(Long et al., 1999). Furthermore, age, sex, substance abuse, andduring working memory tasks directly affect the perfor-
other factors also influence the course of the disease (Frederikse etmance of the task (Stamm, 1969; Brandt et al., 1998;
al., 2000; Gearon and Bellack, 2000; Seeman, 2000). Consequently,Chafee and Goldman-Rakic, 2000). Thus, our model
baseline expression levels of many genes may significantly depend
holds that deficits in expressing multiple PSYN genes on race, sex, age, PMI, and brain pH differences between the sub-
in the PFC of subjects with schizophrenia are partly jects. Hence, combining in a reference sample material from multiple
control brains would create an artificial baseline and may misrepre-responsible for some of the cognitive symptoms associ-
sent the physiological levels of transcripts for any given subject.ated with this disorder. This suggestion is testable in
Second, if the combined racial, PMI, brain pH, and sex differencesanimals, using antisense RNA or conditional knockouts
between samples result in an expression variability for a gene prod-to create hypomorphs, coupled with evaluation of work-
uct that is greater than the disease-specific difference, the reference
ing memory. pool comparison becomes unreliable. However, a pairwise design
The essence of our model incorporates the now widely will still show a consistent and significant change between the
schizophrenic and matched control brain samples.accepted premise of polygenic complexity of schizo-
As there are virtually no consistent gene expression changes re-phrenia (with a spotlight on PSYN genes), which in turn
ported over 2-fold in schizophrenia, the pairwise design in this sys-produces maladaptive responses of developing neural
tem seemed advantageous over a more commonly used referencecircuitry in an experience-dependent fashion, ultimately
pool comparison strategy for microarray studies (Alizadeh et al.,
resulting in clinical manifestations with a common set 2000). In retrospect, however, the ANCOVA and unpaired t test
of phenotypes. In addition, we believe that it may be data for NSF, SYN2, SJAN1, and STAG5 are suggestive that in
the microarray comparisons, at least for some gene expressionpossible eventually to identify different subtypes or etio-
changes, comparison of schizophrenic subjects to a pooled controllogies of schizophrenia produced by different funda-




The experiments were performed on UniGEM-V high-density cDNACharacteristics of Subjects
microarrays (Incyte Pharmaceuticals, Fremont, CA). These cDNATwo groups of subjects, consisting of six and five pairs of schizo-
microarrays test human gene expression using genes and ESTsphrenic and control subjects, were used in these studies. Subject
from the public domain UniGene database. Each array compares apairs were completely matched for sex (18 males and 4 females).
sample to a control by Cy3/Cy5 dual fluorescent hybridization. EachEight subjects were diagnosed with “pure” schizophrenia, while in
UniGEM-V array contains over 7000 unique and sequence verifiedthree subjects the diagnosis was schizoaffective disorder. All but
cDNA elements mapped to 6794 UniGene Homo sapiens annotatedtwo of the schizophrenic subjects were receiving antipsychotic
clusters. The gene names are updated to build 110.medications at the time of death, and five had a history of alcohol
abuse or dependence.
The mean (6 SD) difference within pairs was 4.6 6 3.5 years for Probe Preparation and Array Hybridization
From each subject within a pair, 200 ng of mRNA was labeled withage and 4.4 6 2.7 hr for postmortem interval (PMI). The entire group
of schizophrenic and control subjects did not differ in mean (6 SD) a fluorescent dye (either Cy3 or Cy5) during reverse transcription
and then combined to use as probes for gene expression on theage at time of death (46.5 6 10.7 and 45.1 6 11.5 years, respectively),
PMI (19.4 6 7.1 and 17.7 6 5.0 hr, respectively), brain pH (6.85 6 same microarray. The labeling and hybridization was performed
according to protocols established by Incyte Pharmaceuticals, Inc.0.29 and 6.81 6 0.15, respectively), or tissue storage time at 2808C
(45.4 6 12.3 and 37.7 6 13.1 months, respectively). Consensus If a gene or EST was differentially expressed, the cDNA feature on
the array bound more of the labeled probe from one sample thanDSM-IIIR diagnoses were made for all 22 subjects using data from
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the other, producing either a greater Cy3 or Cy5 signal intensity. assembly protein, clathrin-associated adaptor protein (large, b-1),
dynamin (1 and 2), dynein (axonemal and cytoplasmic), endobrevin,The arrays were scanned at Incyte, the signal intensities were color
coded and downloaded into a local database (SQL Server 7.0). Note kinesin (1, 2, 4 heavy chains), neurexin 1, NSF, P/Q a-1 Ca channel,
rab3a, rabaptin 5, rabphillin 3a, SAP90A, SCAMP 3, SNAP (a andthat the operators were blind to the specific category to which each
sample belonged. Data analysis was performed using GemTools g), synaptotagmin (I, IV, V, VII, IX, XI), syntaxin (1, 3, 4, 5, 7, 8, 16),
syntaxin binding protein (1 and 2), synaptogyrin (1, 2, 3), synapsin(Incyte’s proprietary software). Internal controls were excluded from
the analysis. Gene group data was exported to MS Excel 2000 and (I and II), synaptoporin, calcineurin (b and g), synaptojanin (1 and
2), synaptophysin 1, synaptopodin, vacuolar proton pumps (21 kDa,further analyzed.
42 kDa, 56/58 kDa, 110/116 kDa), vesicle-associated membrane
protein (1, 2, 5, 8), vesicle docking protein p115, voltage-sensitiveMicroarray Data Analysis
Ca channel (b-1, b-3, and g-1 subunits), zinc transporter 4 (RosahlA gene was called present in the sample if all of the following criteria
et al., 1995; Sudhof, 1995; Linial, 1997; Bajjalieh, 1999; Fernandez-were met: (1) the arrayed element was successfully amplified by
Chacon et al., 1999; Jahn and Sudhof, 1999; Janz et al., 1999).PCR; (2) the arrayed element produced signal from at least 40% of
Glutamate system group represented on the microarrays (n 5 11)the spot surface; (3) the signal/background ratio was over 5-fold for
were as follows: AMPA receptors (1, 2, 3), high-affinity aspartate/either the Cy3 or Cy5 probe; and (4) the arrayed element was not
glutamate transporter, kainate receptor 2, metabotropic receptorsa spiked-in control.
(1, 2, 3, 8), NMDA receptor 2c, N-methyl-D-aspartate receptor–Incyte’s control hybridization studies (http://www.incyte.com/
associated protein.gem/GEM-reproducibility.pdf) suggested array data reliability and
GABA system group represented on the microarrays (n 5 18)reproducibility cutoffs as listed below. In addition to this, we per-
were as follows: Betaine/GABA transporter, calbindin 1, calretinin,formed a single control brain hybridization experiment (see Figure
calmodulin, CAM2 kinase, GABAA receptor (b-3, g-2, g-3, p), GABAB1 legend). To assess interexperiment variability, pair 685c/622s was
receptor 1, glutamic acid decarboxylase 1 and 2, parvalbumin, phos-hybridized to three different UniGEM-V microarrays, producing es-
phodiesterase 1b and 1c (calmodulin-dependent), solute carriersentially the same overall results. In summary, our own control data
family 6, SRP72, vesicular GABA/glycine transporter.were consistent with Incyte’s control experiments. Based on these
control data, all expressed gene observations were sorted into one
of the following three categories.
In Situ Hybridization
Balanced Cy3/Cy5 or Cy5/Cy3 Signal Intensity Ratio , 1.59
For in situ hybridization, we designed custom primers for each of
Observations in this category suggested comparable expression
the sequence-verified clones of interest. These primers were used
between the schizophrenic and control sample. In our Cy3/Cy5 con-
to produce ds cDNA molecules of 750–950 bp using PCR and normal
trol experiment (Figure 1A) and in Incyte’s verification study, .95%
human brain cDNA template. The products of these reactions were
of all observations fell into this category. These observations may
ligated into a plasmid vector and transformed into competent E.
contain real differences between samples that are indistinguishable
coli cells. 35S-labeled sense and antisense riboprobes were synthe-
from experimental noise.
sized and purified using Riboprobe In Vitro Transcription System
Balanced Cy3/Cy5 or Cy5/Cy3 Signal Intensity Ratio
(Promega) and RNeasy kit (Qiagen).
between 1.6 and 1.89
Sections (20 mm) from area 9 of each subject in this study were
Observations in this category report a real expression difference
cut on a cryostat and stored on slides at 2808C until processing.
between the schizophrenic and control sample at the 95% confi-
The methods used for in situ hybridization were those of D. B.
dence level. In the control experiments, ,5% of the observations
Campbell, J. B. North, and E. Hess (Campbell et al., 1999), with
fell into this category.
subject pairs always processed together.
Balanced Cy3/Cy5 or Cy5/Cy3 Signal Intensity Ratio $ 1.9
For quantification of the in situ hybridization signal, we used Scion
Observations in this category report a real expression difference
Image (version 3). The investigators were blind to the sample cate-
between the schizophrenic and control sample at the 99% confi-
gory. Uncalibrated optical density (OD) values were measured from
dence level. In the control experiments, ,0.5% of the observations
high resolution scans of X-ray film (X-Omat AR, Kodak) that had
fell into this category.
been exposed to the processed slides for 2–3 days prior to being
developed. The mean relative OD was calculated for each section
Gene Groups in five nonoverlapping rectangular regions with a width of z500 mm
The gene groups related to metabolic pathways, enzymes, and func- and adjusted in length to span cortical layers 2–6. The long axis of
tional pathways are part of GemTools’ gene hierarchy analysis capa- each rectangular region was positioned in parallel with the orienta-
bility. To obtain the list of gene groups, visit http://pittarray.neurobio. tion of cortical cells. The OD of the white matter in the section was
pitt.edu/neuron/. In addition, gene groups related to brain-specific subtracted from each of these measurements to give five relative
functions were designed using recent review articles. UniGEM-V OD values for each subject. For group comparisons, the mean of
microarrays did not contain probes for all known genes related to these five values was used for each subject.
a single gene group. Unless it was certain that only one member of
a given gene family performed a certain synaptic function, all gene
family members represented on the microarrays were included in Monkey Experiments
Two pairs of male cynomolgus (Macaca fascicularis) monkeys,the gene groups (e.g., synaptotagmin I, II, IV, V, VII, IX, XI). To
maximize the potential of novel discovery, isoforms with an uncer- matched for age and weight, were studied. One pair was compared
on the cDNA microarrays, and both pairs were analyzed by in situtain brain expression were also occasionally included in the custom
gene groups (e.g., syntaxin family genes). However, as only ex- hybridization. In each pair, one animal was treated for 10–12 months
with the antipsychotic medication haloperidol decanoate at dosespressed genes were included in the analysis, inclusion of family
members with absent brain expression did not affect the analysis that produced trough serum levels (4–5 ng/ml), known to be in the
therapeutic range for the treatment of schizophrenia. Consistentand interpretation of the data.
The custom-designed gene groups related to brain-specific func- with our attempt to mimic the clinical model of neuroleptic threshold
dosing, all haloperidol-treated animals developed extrapyramidaltions included transcripts for structural proteins, glial markers, neu-
ronal markers, transcription factors, protein kinases, apoptosis symptoms that were effectively controlled with maintenance admin-
istration of benztropine mesylate (Akil et al., 1999; Pierri et al., 1999).markers, growth factors, growth factor receptors, cytokines, adhe-
sion molecules, G proteins, cAMP pathway, DNA binding proteins, The brain tissue was processed identically to the human samples.
For cross-species hybridizations, Incyte required three times themetalloproteinases, heat shock proteins, presynaptic secretory ma-
chinery, GABA system, catecholamine system, glutamate system, amount of mRNA for array hybridization. Based on the detection of
expressed genes, the hybridizations were as successful as the hu-neuropeptides, voltage-gated channels, ligand-gated channels, and
Alzheimer disease-related genes. man sample hybridizations. The in situ analysis of monkey tissue
was performed on areas 9 in sections matched for rostrocaudalGenes in the PSYN group represented on the arrays (n 5 62) were
as follows: clathrin (both light and heavy polypeptides), clathrin coat location.
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Statistical Analysis Jones, E.G. (1996). Selective alterations in gene expression for
NMDA receptor subunits in prefrontal cortex of schizophrenics. J.Microarray Gene Group Analysis
To compare relative levels of expression for genes in the different Neurosci. 16, 19–30.
groups, we employed two types of statistical measures. First, for Akil, M., Pierri, J.N., Whitehead, R.E., Edgar, C.L., Mohila, C., Samp-
individual pairs, chi-square analysis was performed on the distribu- son, A.R., and Lewis, D.A. (1999). Lamina-specific alterations in
tion of genes in a group versus the distribution of all genes called the dopamine innervation of the prefrontal cortex in schizophrenic
present on that microarray. For this analysis, the distribution of gene subjects. Am. J. Psychiatry 10, 1580–1589.
expression ratios was divided into five different bins representative
Alizadeh, A.A., Eisen, M.B., Brown, P.O., and Staudt, L.M. (2000).of confidence intervals for individual gene comparisons: ,21.9;
Distinct types of diffuse large B-cell lymphoma identified by gene
21.89 to 21.6; 21.59 to 1.59; 1.6 to 1.89; and .1.9. Then, a paired
expression profiling. Nature 403, 503–511.t test (df 5 5) was used to compare mean expression ratios for a
Anderson, S., Classey, J., Conde´, F., Lund, J., and Lewis, D. (1995).given gene group to the mean expression ratios for all expressed
Synchronous development of pyramidal neuron dendritic spines andgenes across all six subject pairs.
parvalbumin-immunoreactive chandelier neuron axon terminals inTo distinguish between single gene changes and gene group
layer III of monkey prefrontal cortex. Neuroscience 67, 7–22.changes, we established a list of criteria. In our experiments, we
judged gene group expression to be changed if it met the following Andreasen, N.C. (1996). Pieces of the schizophrenia puzzle fall into
conditions. (1) More than five genes were expressed in the gene place. Neuron 16, 697–700.
group per each subject. (2) By independent statistical measures,
Andreasen, N.C., O’Leary, D.S., Flaum, M., Nopoulos, P., Watkins,
the gene group across the experiment was significantly changed
G.L., Boles Ponto, L.L., and Hichwa, R.D. (1997). Hypofrontality in
(p , 0.05) both by frequency distribution (chi-square test) and cen-
schizophrenia: distributed dysfunctional circuits in neuroleptic-
tral tendency measures (t test) compared to the expression of all
naive patients. Lancet 349, 1730–1734.
genes across the experiments. (3) In each of the individual array
Bajjalieh, S.M. (1999). Synaptic vesicle docking and fusion. Curr.comparisons, the gene group was significantly changed (p , 0.05)
Opin. Neurobiol. 3, 321–328.both by frequency distribution (chi-square test) and central tendency
statistics (t test) compared to the expression of all genes in the Barton, A.J., Pearson, R.C., Najlerahim, A., and Harrison, P.J. (1993).
same experiment. (4) Analyzing the group effect without 5% of the Pre- and postmortem influences on brain RNA. J. Neurochem. 61,
most changed individual genes still showed an overall chi-square 1–11.
and t test significance. (5) No single gene accounted for more than Bertolino, A., Esposito, G., Callicott, J., Mattay, V.S., Van Horn, J.D.,
20% of the group effect. More than 30% of the genes in the group Frank, J.A., Berman, K.F., and Weinberger, D.R. (2000). Specific
contributed to the group effect. relationship between prefrontal neuronal N-acetylaspartate and ac-
In Situ Hybridization Data Analysis–Paired Design tivation of working memory cortical network in schizophrenia. Am.
For each gene, averages are reported as a mean of expression J. Psychiatry 157, 24–34.
changes between schizophrenic-control subject pairs. Because mi-
Bird, T.D., Wijsman, E.M., Nochlin, D., Leehey, M., Sumi, S.M., Pay-croarray data indicated a decrease in gene expression, probabilities
ami, H., Poorkaj, P., Nemens, E., Rafkind, M., and Schellenberg, G.D.for in situ hybridization changes were calculated by a one-tailed t
(1997). Chromosome 17 and hereditary dementia: linkage studiestest in a pairwise design. Unless indicated differently, these pairwise
in three non-Alzheimer families and kindreds with late-onset FAD.comparison statistics are reported throughout the manuscript.
Neurology 48, 949–954.In Situ Hybridization Data Analysis–Group Design
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